Secord, Angeles Alvarez <br/><br/>
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Oct 2012 
 - 5489-98 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-12-0507  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Carboplatin--administration & dosage<br/>Dasatinib<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--administration & dosage<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Thiazoles--administration & dosage<br/>src-Family Kinases--antagonists & inhibitors